Clínica Alemana-ko ikertzaileekin lankidetzan egindako argitalpenak (2)

2018

  1. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

    The Lancet, Vol. 392, Núm. 10142, pp. 123-133

2017

  1. Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status

    PLoS ONE, Vol. 12, Núm. 10